Beksac, M. Et Al. 2023. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome. Clinical Lymphoma, Myeloma and Leukemia , vol.23, no.3 .

Beksac, M., CENGİZ SEVAL, G., Koyun, D., TOPÇUOĞLU, P., YÜKSEL, M., Gurman, G., ... Ilhan, O.(2023). Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome. Clinical Lymphoma, Myeloma and Leukemia , vol.23, no.3.

Beksac, Et Al. "Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome," Clinical Lymphoma, Myeloma and Leukemia , vol.23, no.3, 2023

Beksac, OSMAN Et Al. "Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome." Clinical Lymphoma, Myeloma and Leukemia , vol.23, no.3, 2023

Beksac, M. Et Al. (2023) . "Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome." Clinical Lymphoma, Myeloma and Leukemia , vol.23, no.3.

@article{article, author={ OSMAN İLHAN Et Al. }, title={Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome}, journal={Clinical Lymphoma, Myeloma and Leukemia}, year=2023}